Noticias de AGEN_US

Noticias del mercado

Últimas noticias sobre AGEN_US — 157 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: AGEN_US ✕ 157 resultados
21/04/2026 AGEN_US — The Joplin Globe ES ← PT-PT
Agenus nombra a BAP Pharma como socio global exclusivo para BOT+BAL

Agenus designa a BAP Pharma como socio global exclusivo para BOT+BAL

21/04/2026 AGEN_US — BioSpace ES ← EN
Agenus nombra a BAP Pharma como socio global exclusivo para los programas de acceso BOT+BAL

Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs

21/04/2026 AGEN_US — Investing.com
Agenus presents four abstracts on cancer therapies at ASCO By Investing.com
21/04/2026 AGEN_US — MarketBeat ES ← EN
Agenus Inc. (NASDAQ:AGEN) recibió una calificación promedio de "compra moderada" por parte de las casas de bolsa

Agenus Inc. (NASDAQ:AGEN) Given Average Rating of "Moderate Buy" by Brokerages

21/04/2026 AGEN_US — STT Info
Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs
21/04/2026 AGEN_US — Investing.com Nigeria
Agenus presents four abstracts on cancer therapies at ASCO By Investing.com
21/04/2026 AGEN_US — Investing.com
Agenus presents four abstracts on cancer therapies at ASCO By Investing.com
21/04/2026 AGEN_US — Yahoo Finance
Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026
21/04/2026 AGEN_US — Business Wire
Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026
21/04/2026 AGEN_US — Investing.com
Agenus presents four abstracts on cancer therapies at ASCO By Investing.com
21/04/2026 AGEN_US — Investing.com
Agenus presents four abstracts on cancer therapies at ASCO
21/04/2026 AGEN_US — Business Wire
Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs
21/04/2026 AGEN_US — Stock Titan
Agenus (NASDAQ: AGEN) director Armen receives 3,403 fully vested shares as salary
21/04/2026 AGEN_US — Yahoo Finance
Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs
21/04/2026 AGEN_US — Oncodaily
Promising Phase I Results for BOT/BAL and agenT-797 in PD-1 Refractory Gastroesophageal Cancer
20/04/2026 AGEN_US — Stock Titan
Agenus (NASDAQ: AGEN) asks shareholders to approve 5M shares, highlights BOT+BAL data
20/04/2026 AGEN_US — Yahoo Finance
Is Agenus (AGEN) Outperforming Other Medical Stocks This Year?
20/04/2026 AGEN_US — BioSpace
Agenus cancer cocktail records 0% response rate, missing midstage goal
19/04/2026 AGEN_US — MSN ES ← EN
Agenus (AGEN) presenta nuevos datos clínicos de fase 1b sobre la combinación BOT/BAL para MSS mCRC
18/04/2026 AGEN_US — Investing.com
Agenus reports trial data for cancer drug combination therapy By Investing.com

Página 4 de 8

keyboard_arrow_up